ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
131.791,55
0,09%
S&P 500
5.751,07
0,90%
US Dollar vs BRL
5,50039
0,79%
Bitcoin
62.162,18
0,14%
Brent Oil
77,97
0,00%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Lisata Therapeutics Inc (LSTA)

  7. Lisata Therapeutics Inc (LSTA) Notícias

LSTA

Lisata Therapeutics (LSTA)

Lisata Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:LSTA
DataHoraFonteTítuloCódigoCompanhia
03/10/202409:00GlobeNewswire Inc.Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor EventsNASDAQ:LSTALisata Therapeutics Inc
17/09/202409:00GlobeNewswire Inc.Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER TrialNASDAQ:LSTALisata Therapeutics Inc
09/09/202409:00GlobeNewswire Inc.Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor EventsNASDAQ:LSTALisata Therapeutics Inc
05/09/202409:00GlobeNewswire Inc.Lisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of CholangiocarcinomaNASDAQ:LSTALisata Therapeutics Inc
12/08/202417:05GlobeNewswire Inc.Lisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:LSTALisata Therapeutics Inc
05/08/202409:00GlobeNewswire Inc.Lisata Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update on Monday, August 12, 2024NASDAQ:LSTALisata Therapeutics Inc
18/07/202409:00GlobeNewswire Inc.Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer TherapyNASDAQ:LSTALisata Therapeutics Inc
16/07/202409:00GlobeNewswire Inc.Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line CholangiocarcinomaNASDAQ:LSTALisata Therapeutics Inc
10/07/202409:00GlobeNewswire Inc.Lisata Therapeutics’ Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical ModelNASDAQ:LSTALisata Therapeutics Inc
13/06/202409:30GlobeNewswire Inc.Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX TrialNASDAQ:LSTALisata Therapeutics Inc
28/05/202409:30GlobeNewswire Inc.Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor EventsNASDAQ:LSTALisata Therapeutics Inc
20/05/202409:30GlobeNewswire Inc.Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic CancerNASDAQ:LSTALisata Therapeutics Inc
10/05/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LSTALisata Therapeutics Inc
09/05/202417:13Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LSTALisata Therapeutics Inc
09/05/202417:05GlobeNewswire Inc.Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:LSTALisata Therapeutics Inc
08/05/202409:00GlobeNewswire Inc.Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor EventsNASDAQ:LSTALisata Therapeutics Inc
02/05/202409:00GlobeNewswire Inc.Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024NASDAQ:LSTALisata Therapeutics Inc
23/04/202408:30GlobeNewswire Inc.Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal AdenocarcinomaNASDAQ:LSTALisata Therapeutics Inc
09/04/202409:30GlobeNewswire Inc.Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of OsteosarcomaNASDAQ:LSTALisata Therapeutics Inc
03/04/202409:30GlobeNewswire Inc.Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor EventsNASDAQ:LSTALisata Therapeutics Inc
21/03/202409:00GlobeNewswire Inc.Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of OsteosarcomaNASDAQ:LSTALisata Therapeutics Inc
04/03/202410:00GlobeNewswire Inc.Lisata Therapeutics to Present at the Life Science Investor Forum on March 7ᵗʰNASDAQ:LSTALisata Therapeutics Inc
29/02/202418:05GlobeNewswire Inc.Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:LSTALisata Therapeutics Inc
22/02/202410:00GlobeNewswire Inc.Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern TimeNASDAQ:LSTALisata Therapeutics Inc
20/02/202410:00GlobeNewswire Inc.Lisata Therapeutics to Present at BIO CEO & Investor ConferenceNASDAQ:LSTALisata Therapeutics Inc
18/01/202410:30GlobeNewswire Inc.Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto RicoNASDAQ:LSTALisata Therapeutics Inc
17/01/202410:00GlobeNewswire Inc.Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma MultiformeNASDAQ:LSTALisata Therapeutics Inc
04/01/202410:00GlobeNewswire Inc.Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care TherapyNASDAQ:LSTALisata Therapeutics Inc
12/12/202310:00GlobeNewswire Inc.Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal AdenocarcinomaNASDAQ:LSTALisata Therapeutics Inc
28/11/202318:05GlobeNewswire Inc.Lisata Therapeutics to Present at NobleCon19 Investor ConferenceNASDAQ:LSTALisata Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:LSTA

Seu Histórico Recente

BOV
PRIO3
PETRORIO ON
BOV
IBOV
Índice Bovespa
BOV
TPIS3
TRIUNFO PART ON
BOV
AGXY3
Agrogalaxy Participacoes ON
BOV
UNIP6
UNIPAR PNB
BOV
AZEV4
AZEVEDO PN
BOV
TECN3
TECHNOS ON
BOV
LUPA3
LUPATECH ON
BOV
PINE4
PINE PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados